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Obestatin level and some biochemical parameters in 
type 2 diabetic women attending Mediacl Relief 
Center in Gaza 
 
Abstract 
Background: Obestatin is a novel 23-amino acid peptide derived from the 
mammalian prepro-ghrelin polypeptide. Recent studies demonstrated that 
obestatin is a metabolic hormone associated with type 2 diabetes. Therefore, 
assessment the status of obestatin and clarifying such association in diabetes 
could constitute a promising therapy of the disease. 
Objective: To asses obestatin level and some biochemical parameters 
among type 2 diabetic women attending Mediacl Relief Center in Gaza. 
Materials and Methods: This case-control study comprised 64 type 2 
diabetic women and 64 healthy non diabetic women. Questionnaire interview 
was applied. Serum obestatin was measured by ELISA. Serum glucose, 
cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C) and low 
density lipoprotein cholesterol (LDL-C), urea and creatinine were determined. 
Blood HbA1c was also measured. Data were computer analyzed using SPSS 
version 18.0. 
Results: The mean ages of controls and cases were 52.7±8.9 and 52.9±8.3 
years. Type 2 diabetes was found to be significantly associated with family 
history and diet. More than half of patients had diabetes since less than 5 
years. The main self-reported complications among patients were neuropathy, 
retinopathy and cardiovascular disease. The longer the duration of diabetes, 
the higher the prevalence of self-reported complications. The mean level of 
serum obestatin was significantly lower in diabetic women compared to 
healthy non diabetic controls (3.4±0.8 ng/ml vs. 4.1±1.5 ng/ml, P=0.023).The 
mean HbA1c and glucose levels in cases were significantly higher than that in 
controls (6.4±0.9 and 190.7±86.7 vs 4.7±0.6 and 101.6±21.0) with P=0.000. 
The Pearson correlation test showed negative significant correlations between 
obestatin levels and HbA1c and glucose (r=-0.320, P=0.009 and r=-0.469, 
P=0.000 respectively). The average level of triglycerides was significantly 
increased in diabetic women (183.3±80.0mg/dl) compared to controls 
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(122.4±42.9 mg/dl) with P=0.000. On the other hand, HDL-C was significantly 
lower in cases (40.7±11.2vs. 47.2±12.0mg/dl, % difference=14.8 and t=2.228, 
P=0.030). The Pearson correlation test showed negative significant 
correlations between obestatin levels and triglycerides levels (r=-0.275, 
P=0.026). 
Conclusions: Serum obestatin was significantly lower in diabetic women 
compared to healthy non diabetic women. There were negative significant 
associations between obestatin levels with HbA1c, glucose and triglycerides 
levels. 






















مسحوى الاوبسحاثين وبعض املعايير الكيميائية لدى مرض ى السكري من النوع الثاني من 
مركز الاغاثة الطبية في غزةالاناث اللواجي يرثدن   
لين في  32اكدشف هشمىن الاوبعخاجين حذًثا وهى ًخكىن مً  املقدمة: حمض اميني مشخق مً عذًذ الببديذ بذائي الجٍش
شجبط بمشض العكشي مً الىىع الثاوي  باألًضاظهشث الذساظاث الحذًثت ان الاوبعخاجين هشمىن مخعلق وقذ الثذًياث.  ٍو
                     ولزلك فان جقييم حالت الاوبعخاجين وجىضيح هزا الاسجباط في مشض العكشي ممكً ان ٌشكل عالج واعذ لهزا املشض.
الىىع  تهذف الذساظت الى قياط معخىي هشمىن الاوبعخاجين وبعض املعاًير البيىكيميائيت في مشض ى العكشي مًالهدف: 
                                          الثاوي مً الاهار اللىاحي ًشجذن مشكض الاغازت الطبيت في غضة.
امشأة مصابت  86, املجمىعت املشضيت جحخىي على مجمىعت ضابطت(-اظت )مجمىعت مشضيتمىهج الذس   الطرق والادوات:
امشأة غير مصابت بذاء العكشي. جم الحصىل على البياهاث  86خىي على بالىىع الثاوي مً داء العكشي واملجمىعت الضابطت جح
املعخخذمت في الذساظت مً خالل املقابلت املباششة مع املشض ى. جم قياط معخىي كل مً هشمىن الاوبعخاجين, العكش, 
اجيىين  و , البىليىاتالكىليعترول, الذهىن الثالزيت, البروجين الذهني عالي الكثافت, البروجين الذهني مىخفض الكثاف الكٍش
واًضا جم قياط وعبت اسجباط العكش بالهيمىحلىبين في الذم. جم جحليل البياهاث والىخائج التي جم الحصىل عليها باظخخذام 
                .   spss 0:81  البرهامج الاحصائي املحىظب
 82:± ;738ظىت ومخىظط العمش للمجمىعت املشضيت ھى 7389±;8: كان مخىظط العمش للمجمىعت الضابطت ھى النحائج:
خ العائلي والخغزًت وان اكثر مً هصف مشض ى  العكشي ٌعاهىن مً ظىت. اوضحذ الىخائج ان مشض العكشي ًشجبط بالخاٍس
ل ظىىاث او اقل. كما ان املضاعفاث الشئيعيت التي سجلذ على لعان املشض ى اوضحذ وحىد اعخال العكشي مىز خمغ
ت  واهه كلما صادث مذة الاصابت بالعكشي كلما صادث وعبت  الاعصاب واعخالل الشبكيت وامشاض القلب والاوعيت الذمٍى
وقذ أظهشث الىخائج أن مخىظط معخىي هشمىن ألاوبعخاجين كان أقل في املجمىعت املشضيت مقاسهت املضاعفاث بين املشض ى. 
كاهذ هديجت مخىظط كل مً الجلىكىص ووعبت اسجباط العكش  لت ححصائيت.باملجمىعت الضابطت وقذ كاهذ الىخائج راث دال
بالذم أعلى بذاللت احصائيت في املجمىعت املشضيت منها في املجمىعت الضابطت. وقذ اظهشث الىخائج وحىد عالقت عكعيت بين 
مخىظط معخىي  كاهذ هديجت معخىي هشمىن الاوبعخاجين والجلىكىص ووعبت اسجباط العكش بالهيمىحلىبين )مخضون العكش(. 
الذهىن الثالزيت أعلى بذاللت احصائيت في املجمىعت املشضيت منها في املجمىعت الضابطت. اما معخىي البروجين الذهني عالي 
الكثافت فقذ كان اقل بذاللت احصائيت في املجمىعت املشضيت منها في املجمىعت الضابطت. و اظهشث الىخائج وحىد عالقت 
ت بين الذهىن الثالزيت و معخىي هشمىن ألاوبعخاجين حيث كلما صادث الذهىن الثالزيت كلما قل عكعيت راث داللت احصائي
 معخىي هشمىن ألاوبعخاجين. 
معيييييييخىي هشميييييييىن ألاوبعيييييييخاجين أقيييييييل بذالليييييييت أحصيييييييائيت فيييييييي اليعييييييياء املصييييييياباث بيييييييذاء العيييييييكشي ميييييييً  جبيييييييين ان :الاستتتتتتتح حا ات
يييييييير مصيييييييياباث. جىحييييييييذ عالقييييييييت عكعيييييييييت راث داللييييييييت احصييييييييائيت بييييييييين هشمييييييييىن  ا اهييييييييهكميييييييي الىييييييييىع الثيييييييياوي مقاسهييييييييت مييييييييع اليعيييييييياء الغ
 .ألاوبعخاجين و الجلىكىص ,وعبت اسجباط العكش بالهيمىحلىبين والذهىن الثالزيت
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Diabetes mellitus represents a group of diseases of heterogeneous etiology, 
characterized by chronic hyperglycemia and other metabolic abnormalities, 
which are due to deficiency of insulin action, insulin secretion or both. Two 
major forms of diabetes were identified; type 1 and type 2. Lack of or severe 
reduction in insulin secretion due to autoimmune or viral destructions of β 
cells is responsible for type 1 diabetes, which accounts for 5-10% of diabetic 
patients. The more prevalent form, type 2 diabetes, accounts for more than 
90% of cases (Olefsky, 2001). Type 2 diabetes usually begins as insulin 
resistance, a disorder in which the cells do not use insulin properly. As the 
need for insulin rises, the pancreas gradually loses its ability to produce it 
(Cohen, 2006). 
Lack of insulin action and/or secretion in type 2 diabetes induces hepatic 
glucose output by inhibiting glycogen synthesis and stimulating glycogenolysis 
and gluconeogenesis then increased rates of hepatic glucose production 
result in the development of overt hyperglycemia, especially fasting 
hyperglycemia (Defronzo and Simonson,1992 and Michael et al., 2000). In 
such conditions, lipolysis in adipose tissue is promoted leading to elevated 
circulating levels of free fatty acids. In addition, excess fatty acids in serum of 
diabetics are converted into phospholipids and cholesterol in liver. These two 
substances along with excess triglycerides formed at the same time in liver 
may be discharged into blood in the form of lipoproteins (Jaworski et al., 
2007). In addition, disturbance in serum urea and creatinine was also reported 
in type 2 diabetes (Sharma et al., 2011 and Yassin et al., 2011). 
Obestatin is one of the three ghrelin gene products. It is a novel 23-amino 
acid peptide derived from the mammalian prepro-ghrelin polypeptide (Zhang 
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et al., 2005). The expression of obestatin was reported in cells of the gastric 
mucosa, myenteric plexus and perinatal pancreas and in Leydig cells of the 
testis (Zhang et al., 2005; Chanoine et al., 2006 and Dun et al., 2006). 
Obestatin binds to an orphan G protein-coupled receptor, termed GPR39, to 
inhibit food intake (Zhang et al., 2005). On the other side, obestatin 
manifested various biological functions, such as improving memory 
performance, causing anxiolytic effects (Carlini et al., 2007), inhibiting thirst in 
rats (Samson et al., 2007), activating cortical neurons (Dun et al., 2006), 
stimulating proliferation of retinal pigment epithelial cells in vitro (Camiña et 
al., 2007), and profoundly influencing sleep (Szentirmai and Krueger, 2006b 
and Szentirmai et al., 2009). 
There is great controversy about the effects of obestatin on food intake with 
some studies suggesting that it may inhibit food intake and suppress body 
weight under basal and ghrelin-stimulated conditions (Bresciani et al., 2006; 
Zizzari et al., 2007 and Hassouna et al., 2010) and others suggesting no 
effect (Seoane et al., 2006 and Gourcerol et al., 2007). In addition, articles 
linked obestatin and diabetes mellitus were very few and recent. Obestatin 
status in type 2 human diabetes remains controversial. One study showed 
decreasing concentration of obestatin with type 2 diabetes and impaired 
glucose regulation and insulin resistance (Qi et al., 2007). In another study, 
St-Pierre et al., (2010) showed that normal and diabetic subjects displayed 
similar levels of circulating obestatin in fasting condition. However, patients 
with type 2 diabetes looked refractory to the inhibitory effect of meal on 
obestatin secretion. Regarding lipid metabolism, it was reported that obestatin 
treatment led to decrease in plasma triglycerides (Nagaraj et al., 2008 and 
2009 and Agnew et al., 2011). 
Although the prevalence of diabetes in Gaza Strip is alarming, the available 
studies are limited and biochemical data are only restricted to traditional tests 
when the patient visits the clinic. However, a recent study investigated the 
status of leptin hormone in type 2 diabetic patients in Gaza Strip (Altawil, 
2009). No previous study was conducted on the novel hormone obestatin in 
type 2 diabetes in Gaza Strip or even in the Arab World. Therefore, this study 
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will be the first study to assess obestatin status in type 2 diabetic females in 
Gaza Governorate, Gaza Strip. 
 
1.2 General objective 
The general objective of the present study is to assess obestatin level and 
some biochemical parameters in type 2 diabetic women attending Medical 
Relief Center in Gaza. 
 
 
1.3 The specific objectives were: 
1. To investigate obestatin level in type 2 diabetic women and compared them 
with healthy controls. 
2. To determine HbA1c in blood and serum glucose, lipid profile including 
cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C) and low 
density lipoprotein cholesterol (LDL-C), urea and creatinine in diabetic 
patients and controls. 
3. To study sociodemographic and clinical data in type 2 diabetic patients. 
4.To verify the relationships of obestatin with the previous parameters.  
 
1.4 Significance 
1. Diabetes mellitus is prevalent globally as well as in the Gaza Strip, and 
leads to high rates of morbidity and mortality. 
2. Globally, there are few studies linked obestatin with type 2 diabetes. Of 
course, this will be the first study to describe obestatin levels in type 2 diabetic 
patients in Gaza Strip or even in the Arab world. 
3. Understanding the role of obestatin in diabetes mellitus may make it a 










2.1 Definition of diabetes mellitus 
It is a metabolic disorder characterized by chronic hyperglycemia due to 
disturbances of carbohydrate, fat and protein metabolism that are associated 
with absolute or relative deficiencies in insulin secretion, insulin action or both. 
Diabetes poses a major and growing health and socio-economic burden on 
society that affects over 177 million people worldwide and this figure is likely 
to be more than double by the year 2030 (WHO, 2003).  
 
2.2 Types of diabetes 
The most common types of diabetes mellitus are:  
2.2.1 Type 1 diabetes 
Type 1 diabetes indicates the processes of beta-cell destruction that may 
ultimately lead to diabetes mellitus in which insulin is required for survival to 
prevent the development of ketoacidosis, coma and death. It is characterized 
by the presence of islet cell or insulin antibodies which lead to beta cell 
destruction. Type 1 diabetes accounts for 5-10% of all diagnosed cases of 
diabetes (Olefsky, 2001). Despite 30 years of research, the cause of type-1 
diabetes remains unknown (Wilkin, 2006). 
2.2.2 Type 2 diabetes 
Type 2 diabetes mellitus is a heterogeneous syndrome which accounts for 
about 90-95% of all diagnosed cases of diabetes. The causes of type 2 
diabetes are multi-factorial and caused by a group of both genetic and 
environmental elements that affect beta-cell function and tissue (muscle, liver, 
adipose tissue, pancreas) insulin sensitivity (Scheen, 2003). Type 2 diabetes 
develops in individuals who fail to compensate for insulin resistance by 
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increasing pancreatic insulin secretion. This insulin deficiency results from 
pancreatic beta-cell dysfunction and death (Cnop, 2008). 
 
2.2.3 Gestational diabetes 
Gestational Diabetes (GD) is defined as any degree of glucose intolerance 
which begins or is first recognized during pregnancy. The risk for developing 
type 2 diabetes within the first decade following pregnancy in GD cases 
ranges between 35% and 60% (Wroblewska-Seniuk et al., 2009). Similarly, 
children of women with GD are known to be at risk for obesity and diabetes 
mellitus in their later life (Bánhidy et al., 2011). 
 
2.3 Prevalence and mortality rate of diabetes mellitus 
in Palestine 
The prevalence of diabetes mellitus in Palestine was examined in a study 
conducted in 2000 in cooperation with Al-Quds University and Ministry of 
Health. The results indicated that the prevalence was about 9% (Ministry of 
Health, 2002). It is around the reported prevalence rate in Egypt and Tunisia 
(9%) and less than in Saudi Arabia (12%) and Oman (13%). However, in 
Palestine, there is under-diagnosis and under-reporting of the disease. This is 
due to lack of proper hospital and clinic recording system (Ministry of Health, 
2005). The mortality rate of diabetes mellitus among Palestinians constituted 
5.9 per 100,000 population in the year 2009 (Ministry of Health 2009), and this 








2.4 Type 2 diabetes 
2.4.1 Metabolism in type 2 diabetes 
Circulating glucose is derived from 1) intestinal absorption during the fed state 
in which the rates of gastric emptying determine how quickly glucose appears 
in the circulation during the fed state, and from 2) hepatic processes including 
glycogenolysis and gluconeogenesis. Renal gluconeogenesis contributes 
substantially to the systemic glucose pool only during periods of extreme 
starvation. Although most tissues have the ability to hydrolyze glycogen, only 
the liver and kidneys contain glucose-6-phosphatase, the enzyme necessary 
for the release of glucose into the circulation. 
The rate of glucose entering the circulation balanced by the rate of glucose 
removal from the circulation. The glucoregulatory hormones of the body are 
designed to maintain circulating glucose concentrations in a relatively narrow 
range. Glucoregulatory hormones include insulin, glucagon, amylin, glucagon-
like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), 
epinephrine, cortisol, and growth hormone. Of these, insulin and amylin are 
derived from the β-cells, glucagon from the α-cells of the pancreas, and GLP-1 
and GIP from the L-cells of the intestine. 
In the bi-hormonal model of glucose homeostasis, insulin is the key regulatory 
hormone of glucose disappearance, and glucagon is a major regulator of 
glucose appearance. After reaching a post-meal peak, blood glucose slowly 
decreases during the next several hours, eventually returning to fasting levels. 
In the immediate post-feeding state, glucose removal into skeletal muscle and 
adipose tissue is driven mainly by insulin. At the same time, endogenous 
glucose production is suppressed by 1) the direct action of insulin on the liver, 
and 2) the paracrine effect or direct communication within the pancreas 
between the α- and β-cells, which results in glucagon suppression (Wallum et 
al., 1992). 
Type 2 diabetes is a disorder characterized by lack of insulin action and/or 
secretion that induces hepatic glucose output by inhibiting glycogen synthesis 
and stimulating glycogenolysis and gluconeogenesis then increased rates of 
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hepatic glucose production result in the development of overt hyperglycemia, 
especially fasting hyperglycemia (Defronzo and Simonson,1992 and Michael 
et al., 2000). 
In such conditions, lipolysis in adipose tissue is promoted leading to elevated 
circulating levels of free fatty acids. Ketones are produced, and are found in 
large quantities in ketosis, the liver converts fat into fatty acids and ketone 
bodies which can be used by the body for energy (Botion and Green, 1999). 
In addition, excess fatty acids in serum of diabetics are converted into 
phospholipids and cholesterol in liver. These two substances along with 
excess triglycerides formed at the same time in liver may be discharged into 
blood in the form of lipoproteins (Jaworski et al., 2007). Several studies 
showed that cholesterol, triglycerides and LDL-C are elevated in diabetic 
patients (Barrett-Connor et al., 1982). In contrast, other studies documented 
that HDL-C was decreased (Yassin et al., 2011). In addition, disturbance in 




2.4.2 Complications of type 2 diabetes mellitus 
Complications of type 2 diabetes include acute and chronic complications. 
The acute complications comprise diabetic ketoacidosis, hyperosmolar 
hyperglycemic non ketotic coma, lactic acidosis and hypoglycemia (Bardin, 
C.W. 1994 and Harris et al., 1995). The chronic complications include 
cardiovascular disease, peripheral vascular disease, cerebrovascular disease, 
diabetic retinopathy and diabetic nephropathy (Savage, 1996; Dyck et al., 
2002; Bate and Jerums, 2003; Susztak et al., 2003 and The National Eye 
Institute, 2006). Other complications include foot problems and leg 
amputations, skin disorders, decreased cognitive abilities and dementia, 
sexual dysfunction, pregnancy complications, some types of cancer, yeast 
infections, urinary tract infections, gingivitis, thrush, tuberculosis and other 





The risk of developing diabetic retinopathy or other microvascular 
complications of diabetes depends on both the duration and the severity of 
hyperglycemia. Retinopathy may begin to develop as early as 7 years before 
the diagnosis of diabetes in patients with type 2 diabetes. Retinopathy 
involves changes in the retina. These changes happen because of damage or 
growth problems in the small blood vessels of the retina. Usually, changes in 
the retinal blood vessels don't appear before a person has reached puberty. 
One reason why diabetes needs to have regular yearly eye exams is because 
people with retinopathy may not have any problems seeing at first. But if the 
condition gets worse, they can become blind. A person with diabetes may be 
able to slow or reverse the damage caused by retinopathy by improving blood 
sugar control. If retinopathy becomes more advanced, laser treatment may be 
needed to help prevent vision loss (The National Eye Institute, 2006). 
2.4.2.2 Diabetic neuropathy 
Diabetic neuropathy can affect nerves in many different parts of the body. The 
most common early symptoms of the condition are numbness, tingling, or 
sharp pains in the feet or lower legs. An estimated 50% of those with diabetes 
have some form of neuropathy, but not all with neuropathy have symptoms. 
The highest rates of neuropathy are among people who have had the disease 
for at least 25 years. Diabetic neuropathy also appears to be more common in 
people who have had problems controlling their blood glucose levels, in those 
with high levels of blood fat and blood pressure, overweight people, and 
people over the age of 40 (Dyck et al., 2002). If it's not treated, nerve damage 
can cause a number of problems. For example, because of the numbness, 
people with nerve damage might not realize that they have a cut, and it could 
become seriously infected before they discover it (Debra Manzella, 2006). 
2.4.2.3 Cardiovascular disease 
Cardiovascular disease is the number one killer of people with type 2 
diabetes, people with diabetes developing certain problems with the heart and 
blood vessels. Some of these problems are Heart attack, stroke and blockage 
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of blood vessels in the legs and feet, which can lead to foot ulcers, infections, 
and even loss of a toe, foot, or lower leg (Marshall, 2006). Myocardial 
ischemia due to coronary atherosclerosis commonly occurs without symptoms 
in patients with diabetes. As a result, multivessel atherosclerosis often is 
present before ischemic symptoms occur and before treatment is instituted. A 
delayed recognition of various forms of coronary heart disease undoubtedly 
worsens the prognosis for survival for many diabetic patients. One reason for 
the poor prognosis in patients with both diabetes and ischemic heart disease 
seems to be an enhanced myocardial dysfunction leading to accelerate heart 
failure. Several factors probably underlie diabetic cardiomyopathy: severs 
coronary atherosclerosis, prolonged hypertension, chronic hyperglycemia, 
microvascular disease, glycosylation of myocardial proteins, and autonomic 
neuropathy (Savage, 2005). 
 
2.5 Obestatin 
2.5.1 Definition and site of secretion 
Obestatin is a novel 23-amino acid peptide derived from the mammalian 
prepro-ghrelin polypeptide, with molecular weight 2546.8 (Zhang et al., 2005). 
The expression of obestatin was reported in cells of the gastric mucosa, 
myenteric plexus and perinatal pancreas, mammary gland, breast milk, Leydig 
cells of the testis, spleen and in plasma and saliva (Zhang et al., 2005; 
Chanoine et al., 2006; Dun et al., 2006; Aydin et al., 2008; Grönberg et al., 
2008 and Ozbay et al., 2008). 
 
2.5.2 Biosynthesis 
Obestatin is one of the three ghrelin gene products. The sequential steps of 
the production of three ghrelin genes products and their relationship with 
ghrelin O-acyltransferase (GOAT) is illustrated in Figure 2.1 (Chen et al., 
2009).The described wild-type human ghrelin mRNA codes for a 117 amino 
acid long peptide, preproghrelin. Preproghrelin contains a 23 amino-acid 
signal peptide and a 94 amino-acid called pro-ghrelin (1–94). This includes 
the 28 amino acid mature ghrelin (1–28) and a 66 amino acid tail (29–94) 
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(Jeffery et al., 2005). Recent evidence suggests that the 66 amino acid tail of 
wild type proghrelin (29–94) can circulate as a full-length peptide (C ghrelin) 
or be processed to smaller peptides, mainly obestatin. There may be two 
types of C-ghrelin: one derived from the wild type proghrelin and one derived 






Figure 2.1. A diagram illustrating sequential steps of the production of three ghrelin 
genes products and their relationship with ghrelin O-acyltransferase, GOAT(Chen et 
al., 2009). 
 
2.5.3 Obestatin in plasma and its degradation 
Similar to ghrelin and growth hormone, obestatin is secreted in a pulsatile 
manner. Obestatin and ghrelin amounts in human plasma were found to be 
6.9±0.28 and 132.4±13.1 fmol/ml, respectively with ratio of obestatin to ghrelin 
(%) 5.21 (Mondal et al. 2008). Plasma obestatin was below the detectable 
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value (less than 0.2 fmol) in rats. Differences in the metabolic degradation 
kinetics of human obestatin and mouse obestatin were found in plasma, liver 
and kidney, with half- lives ranging between 12.6 and 138.0 min (Vergote et 
al., 2008). 
 
2.5.4 Biological effects of obestatin 
It was originally projected that obestatin binds to an orphan G protein-coupled 
receptor, termed GPR39 (Zhang et al., 2005). High levels of GPR39 mRNA 
were found abundantly in the amygdala, the hippocampus, and the auditory 
cortex but not in the hypothalamus (Jackson et al., 2006). However, Lauwers 
et al., (2006) indicated that obestatin is not the endogenous cognate ligand for 
GPR39, whereas a more recent study demonstrated that obestatin was a 
metabolic hormone capable of binding to GPR39 and, in turn, of regulating the 
diverse biological functions of gastrointestinal and adipose tissues (Zhang et 
al., 2008). Furthermore, Granata et al. (2008) reported that obestatin 
promotes beta cell and human islet survival by binding to glucagon-
likepeptide-1 receptor (GLP-1R), the receptor through which incretins act. 
Similarly, incretins also reduce gastrointestinal motility with a paracrine 
peripheral action and induce satiety and reduce food intake in the hindbrain 
specifically in the postrema and nucleus of the solitary tract (Yamamoto et al., 
2003 and Holst, 2007). To date, the receptor for obestatin remains unknown 
and further studies are required to reveal the exact relationship between 
obestatin, GPR39 and GLP-1R.  
 
2.5.4.1 Appetite and body weight 
There is great controversy about the effects of obestatin on food intake with 
some studies suggesting that it may inhibit food intake and suppress body 
weight under basal and ghrelin-stimulated conditions (Zhang et al., 2005; 
Bresciani et al., 2006 and Zizzari et al. 2007), and others suggesting no effect 
(Seoane et al., 2006 and Gourcerol et al., 2007). Recent studies have partially 
clarified this issue. In one of these studies, intraperitoneal obestatin 
suppressed food intake and body weight gain in rodent in a U-shaped dose–
response relationship. This relationship may explain the difficulties in 
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reproducing the effects of obestatin on feeding reported by some groups 
(Lagaud et al., 2007). In the other study, intracerebroventricular administration 
of obestatin inhibited water drinking in ad libitum-fed and - watered rats, and 
in food- and water-deprived animals (Samson et al., 2007).The effects on 
water drinking preceded and were more pronounced than any effect on food 
intake, and did not appear to be the result of altered locomotor/behavioral 
activity. Thus, it appears that obestatin possess biologic activity but that the 
effect on food intake may be secondary to an initial action in inhibiting thirst 
phenomenon referred to by some authors as dehydration anorexia (Samson 




Data regarding effects of obestatin on insulin secretion are limited and 
controversial as stimulation (Granata et al., 2008), inhibition (Qader et al., 
2008), and lack of effect (Green et al., 2007) have been reported. Further 
studies are necessary to clarify this issue and the effects of obestatin on 
glucose-sensing neurones, insulin action and hepatic glucose production. In 
addition, previous studies suggest that obestatin is involved in lipid 
metabolism. Nagaraj et al. (2008 and 2009) reported that 8-day obestatin 
treatment led to 22-32% decrease of plasma triglyceride levels. Agnew et al. 
(2011) did not observe any changes in fasting cholesterol levels following 14-
day continuous infusion with obestatin, however obestatin led to a significant 
40% reduction in plasma triglyceride levels.  
 
2.5.4.3 Growth hormone secretion 
Most studies showed that neither intravenous nor intracerebroventricular 
administration of obestatin affects the secretion of growth hormone (GH) in 
rats (Bresciani et al., 2006 and Yamamoto et al., 2007). Nevertheless, one 
study showed that obestatin, in some conditions, can inhibit exogenous 
ghrelin action on GH release (Zizzari et al., 2007). It remains to be determined 






Data regarding obestatin effects on reproductive function are very limited. A 
recent study demonstrated that obestatin may directly control porcine ovarian 
granulosa cells functions, stimulating proliferation and apoptosis of these cells 
and the secretion of progesterone (Mészárosová et al., 2008). 
 
2.5.4.5 Gastrointestinal function 
Recently, obestatin was demonstrated to stimulate the secretion of pancreatic 
juice enzymes through a vagal pathway in anaesthetized rats (Kapica et al., 
2007). As with the effects of obestatin on regulation of food intake, its effects 
on gastrointestinal motility are involved in great controversy with most studies 
reporting no effect (Bassil et al., 2007; De Smet et al., 2007; Gourcerol et al., 
2007; Depoortere et al., 2008 and Chen et al., 2010), and others reporting a 
negative effect (in gastric and jejunal motility) under basal and ghrelin-
stimulated conditions (Zhang et al., 2005). Further studies should clarify this 
issue and its effects on gastric exocrine secretion and epithelial protection. 
 
2.5.4.6 Cellular proliferation 
Obestatin may also be able to influence cell proliferation and apoptosis. It was 
demonstrated that obestatin induces cell proliferation in primary cultures of 
human retinal epithelial cells by MEK/ERK 1/2 phosphorylation (Camiña et al., 
2007) and promotes human islets cells survival through cAMP increase and 
involvement of AC/cAMP/PKA signaling (Granata et al., 2008). 
 
2.5.4.7 Bone physiology 
Data regarding effects of des-acyl ghrelin and obestatin on bone physiology 
are very limited. A recent study demonstrated that des-acyl ghrelin stimulates 
human osteoblasts proliferation in the absence of GHS-R1a (Delhanty et al., 
2006). Unlike ghrelin, obestatin does not exert any relevant activity in 







2.5.4.8 Other effects 
Neither intravenous nor intracerebroventricular administration of obestatin 
affects the secretion of prolactin, thyroid stimulating hormones and 
adrenocorticotropic hormone in rats (Bresciani et al., 2006 and Nogueiras et 
al., 2007). On the other hand, a recent report provides evidence indicating 
that obestatin effects are functionally opposite on anxiety to that of ghrelin, 
while both these related peptides increase memory retention (Carlini et al., 
2007). Recently, it was demonstrated that obestatin has also a sleep-






















2.6 Related studies 
Catalán et al. (2007) evaluated the actual presence of obestatin receptor 
(GPR39) mRNA in human adipose tissue and whether GPR39 expression 
levels are altered in obesity and obesity-associated type 2 diabetes. Omental 
adipose tissue biopsies obtained from 15 women were used in the study. 
Patients were classified as lean (BMI=20.8±1.0 kg/m2), obese 
normoglycaemic (BMI=48.4±2.1 kg/m2) and obese type 2 diabetic patients 
(BMI=52.6±4.9 kg/m2). Obese type 2 diabetic patients exhibited significantly 
lower GPR39 expression levels compared to lean (P=0.016) and obese 
normoglycaemic subjects (P=0.008), while no differences between lean and 
obese normoglycaemic patients were observed. The mRNA expression levels 
of GPR39 were negatively correlated to fasting glucose concentrations (r=-
0.581, P=0.023), while exhibiting a positive correlation to adiponectin mRNA 
expression levels (r=0.674, P=0.006). The authors concluded that the reduced 
expression levels of GPR39 in omental adipose tissue observed in obese type 
2 diabetic patients suggest an involvement of obestatin signalling in glucose 
homeostasis and type 2 diabetes development. 
 
Qi et al. (2007) investigated whether plasma obestatin level is different in 
patients with impaired glucose regulation (IGR) and type 2 diabetes mellitus 
(T2DM). Forty-seven patients with T2DM, 30 subjects with IGR, and 38 sex- 
and age-matched normal controls participated in the study. Plasma obestatin 
levels were lower in patients with T2DM and IGR than in controls (37.5±9.2 
ng/l and 39.2±9.7 ng/l vs. 43.8±8.0 ng/l, P=0.002 and P=0.039, respectively). 
Decreasing concentrations of obestatin were independently and significantly 
associated with IGR and T2DM. Multiple logistic regression analysis revealed 
obestatin to be independently associated with IGR and T2DM. In a multiple 
linear regression analysis, only waist-to-hip ratio and homeostasis model 






Basal plasma obestatin levels were investigated in 321 normal weight and 
obese subjects in relation to BMI, gender, age, insulin concentrations, and 
type 2 diabetes (Lippl et al., 2008). Additionally, postprandial obestatin levels 
were determined in 20 normal weight subjects. Basal obestatin levels in 
females were higher compared to males (193.6±5.8 vs. 140.6±5.1 pg/ml). 
Obestatin levels correlated inversely and significantly with BMI (f: r=-0.632, 
p<0.001; m: r=-0.487, p<0.001) and basal insulin levels (f: r=-0.536, p<0.001; 
m: r=-0.320, p=0.008) in females and males. However, in a multiple 
regression analysis as well as in a matched comparison of a low and high 
insulin group no significant relationship between insulin and obestatin levels 
was observed in nondiabetics. On the other hand, inclusion of type 2 diabetics 
with higher insulin levels resulted in a significant inverse correlation. Obestatin 
levels were independent of age in both sexes. In patients with type 2 diabetes 
basal obestatin levels were not different compared to nondiabetic subjects 
when matched for gender, body mass index, and insulin. In normal weight 
subjects, postprandial obestatin levels showed a significant decrease between 
60 and 90 minutes rising to basal levels thereafter.  
 
St-Pierre et al. (2010) clarified obestatin secretion in normal subjects and in 
patients with type 2 diabetes in basal conditions and after a standardized 
meal. Five normal subjects and 5 type 2 diabetic patients were studied during 
infusion of saline (iv for over 5 h from -120 to +180 min). A standardized lunch 
was served at 0 min. Obestatin, glucose, and insulin levels were assayed at -
120, -90, -60, -45, -30, -15, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min. From 
-120 to 0 min, obestatin levels in normal and type 2 diabetic patients were 
similar (area under the curve: 32.3±5.6 pg/ml/min vs 31.1±1.0 pg/ml/min). 
After the meal, circulating obestatin levels underwent a clear decrease in 
normal subjects (0 min: 300.6±34.7 pg/ml vs nadir at 60 min: 161.8±29.4 
pg/ml; p=0.002) but not in diabetic patients (0 min: 267.2±16.5 pg/ml vs nadir 
at 180 min: 226.0±10.5 pg/ml). 
 
Jack, (2012) measured fasting plasma obestatin concentrations of the 
subjects devided in type 2 diabetes (T2DM), impaired glucose tolerance (IGT) 
and normal glucose tolerance (NGT) to investigate the relationship between 
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obestatin and fasting plasma glucose (FPG), 2 hour plasma glucose (2hPG), 
fasting plasma insulin (FIns), insulin resistance (IR) and plasma lipid as well 
as other factors in population with different glucose tolerances. Plasma 
obestatin levels were measured by radioimmunoassay. The relationship 
between plasma Obestatin levels and BMI, the homeostasis model 
assessment of insulin resistance (HOMA-IR), plasma glucose, insulin, blood 
lipids levels were also analyzed by bivariate, and multivariate regression 
analysis. Plasma obestatin levels in patients with IGT and T2DM were 
significantly reduced compared with controls (2.41±0.78 ng/ ml) and 
(2.95±0.56 ng/L) vs (3.41±0.61 ng/ ml), P= 0.01. Plasma obestatin levels were 
also found to be markedly decreased in obese subjects in three groups when 
compared to subject with BMI 25 kg/m². Plasma obestatin levels correlated 
negatively with systolic blood pressure (SBP), diastolic blood pressure (DBP), 
BMI, waist to hip ratio (WHR), FPG, 2hPG, Fins, HOMA-IR, triglycerides, LDL-
C, C-reactive protein (P<0.01 and P<0.05) in simple regression analysis. But 
in a multiple regression analysis, only BMI and FPG were independently 
associated with plasma obestatin levels (P<0.01). In non-obese groups only 













Materials and Methods 
 
3.1 Study design 
Case control study design.  
 
3.2 Study population 
The target population was type 2 diabetic women aged 40-65 years attending 
Medical Relief Center in Gaza Governorate. Healthy non diabetic women 
were   served as controls. 
 
3.3 Sampling and sample size 
Non probability accidental sample of type 2 diabetic women, previously 
diagnosed according to the WHO diagnostic criteria for diabetes (World 
Health Organization, 2006), were selected as cases from Medical Relief 
Center in Gaza Governorate. Healthy non diabetic women were served as 
controls. Cases and controls were matched with age. The sample size was 
128 women (64 type 2 diabetic women and 64 healthy non diabetic women). 
 
3.4 Exclusion criteria 
Women aged <40 and >65 years 
Women with blood pressure >140/90 
Pregnant women 




3.5 Ethical Considerations 
The necessary approval to conduct the study was obtained from the local 
ethical committee in the Gaza Strip. 
 
3.6 Data collection 
3.6.1 Questionnaire interview 
A meeting interview was used for filling in a questionnaire which designed for 
matching the study need for both cases and controls (Annex 1). All interviews 
were conducted face to face by the researcher himself. During the survey the 
interviewer explained any of the questions that were not clear. The 
questionnaire was based on the questions of a previous study with some 
modifications (Altawil, 2009). Most questions were the yes/no questions which 
offer a dichotomous choice (Backestrom and Hursh-Cesar, 1981). The validity 
of the questionnaire was tested by six specialists in the fields of epidemiology, 
public health, endocrinology and nutrition. The questionnaire was piloted with 
10 patients. The questionnaire included questions on the sociodemographic 
data of the study population (age, education and family history), diet and drug 
therapy, and clinical data including duration of DM and the most important 
complications of diabetes. 
 
3.6.2 Body mass index 
Body mass index was calculated as the ratio of body weight in Kg/height in 
square meter. Women were asked to remove heavy clothes and shoses 
before measurement of weight and height. Medical balance (Seca Model 762, 
Germany) was used for weight measurement. Women with BMI=18.5–24.9 
were considered to have normal weight and women with BMI≥30.0 were 







3.6.3 Specimen collection and biochemical analysis 
Twelve hours fasting overnight venous blood samples were collected from 64 
type 2 diabetic women and 64 healthy non diabetic controls. Blood samples (6 
ml each) were drawn by the researcher herself, who had a Bachelor Degree 
of Medical Technology, into vacutainer and plastic tubes from each control 
and diabetic women. About 2 ml blood was placed into EDTA vacutainer tube 
to perform HbA1C for cases and controls. One ml blood was placed into a 
plastic tube contained 10 µl protease inhibitor cocktail supplied by sigma-
Aldrich Germany with catalog number (P8340) for serum obestatin assay. The 
remainder quantity of blood (3 ml) was placed in plastic tube for glucose, 
cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), urea and creatinine determination. 
The blood (one and 3 ml samples) was left for a while without anticoagulant to 
allow blood to clot. Serum samples were obtained by centrifugation at 3000 
rpm for 10 minutes. Serum with protease inhibitor cocktail tubes were stored 
at –30±5° Cfor serum obestatin assay. However, serum analysis for glucose, 
lipid profile, urea and creatinine was done immediately.  
 
3.7 Biochemical analysis 
3.7.1 Determination of serum obestatin 
Determination of human serum obestatin level was carried out by competitive 
enzyme immunoassay (ELISA) for the quantitative determination of obestatin 
in human serum and plasma Catalog number 48-OBEHU-E01 Size: 96 wells, 
Alpco diagnostics, USA. 
Assay principle 
This EIA kit for determination of obestatin in human plasma or serum samples 
is based on a competitive enzyme immunoassay using the combination of 
highly specific antibody to human obestatin and biotin–avidin affinity system. 
The 96 wells plate is coated with goat anti rabbit IgG, to which biotinylated 
human obestatin, human obestatin standard or samples and rabbit antihuman 
obestatin antibody are added for competitive immunoreaction. After incubation 
and plate washing, horse radish peroxidase (HRP) labeled streptavidin (SA) is 
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added, so that HRP labeled SA-biotinylated human obestatin-antibody 
complex is formed on the surface of the wells. Finally, HRP enzyme activity is 
determined by 3, 3,5,5’-Tetramethylbenzidine (TMB) and the concentration of 








Note: Before starting assay, all the reagents were brought to room 
temperature (20-25°C) except samples. Protease inhibitor added serum and 
plasma samples were kept in an ice-bath after separation or during thawing 
from freezing and were used in as soon as possible.  
Equipment required 
1. Photometer for microtiter plate (plate reader), which can read extinction 2.5 
at 450nm. 
2. Washing device for microtiter plate and dispenser with aspiration system. 
3. Micropipettes, multi-channel pipettes for 8 wells or 12 wells and their tips 
(20μL-1mL). 
4. Test tubes (glass or polypropylene) for preparation of standard solution 
 Component Form Quantity Main ingredient 




1 Plate (96 
wells) 
Goat anti rabbit IgG 
2 Standard Lyophilized 
powder 
1 Vial (50ng) Synthetic human 
obestatin 
3 Labeled Antigen Lyophilized 
powder 
1 Vial Biotinylated human 
obestatin 
4  Specific Antibody Liquid 1 Bottle (6mL) Rabbit anti human 
obestatin antibody 









7  Reaction Stopping 
Solution 
Liquid 1 Bottle 
(12mL) 
1M H2SO4 
8  Buffer Solution Liquid 1 Bottle 
(25mL) 
BSA containing saline 
buffer 
9  Concentrated 
Wash Solution 
Liquid 1 Bottle 
(25mL) 
Concentrated saline 
10  Adhesive Foil  3 Sheets  
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5. Graduated cylinder (500mL or 1,000mL). 
6. Distilled or deionized water. 
7. Lint free paper towel. 
8. A microplate shaker if necessary. 
 
Preparatory work 
1. Preparation of standard solution: 
The Standard (lyophilized human obestatin 50ng/vial) was reconstituted with 
0.5mL of Buffer Solution, which affords 100ng/mL standard solution. The 
reconstituted standard solution (0.1mL) was diluted with 0.2mL of Buffer 
Solution that yields 33.333ng/mL standard solution. The same dilution to 
make each standard solution of 11.111, 3.704, 1.235, and 0.412 ng/mL. 
Buffer Solution was used as 0 ng/mL. 
2. Preparation of labeled antigen solution: Reconstitute Labeled Antigen with 
6mL of Buffer Solution was reconstituted. 
3. Preparation of washing solution: A volume of 25mL of Concentrated Wash 
Solution was diluted to 500mL with distilled or deionized water. 
4. Other reagents were ready for use. 
 
Procedure > 
1. Three hundred microliter of washing solution was added to each well and 
kept for at least 30 seconds, then the washing solution was aspirated in the 
wells. The plate was inverted and tapped firmly on a lint free paper towel to 
ensure blotting free of most residual washing solution. 
2. Fifty microliter of labeled antigen solution was filled into each well first, then 
20μL of each of standard solutions (0, 0.412, 1.235, 3.704, 11.111, 33.333, 
100ng/mL) or samples was introduced and finally 50μL of human obestatin 
antibody solution was added into each well. 
3. The plate was covered with Adhesive Foil and was incubated at 4°C for 18 
- 20 hours with additional 30 minutes at room temperature (still or shaking). 
4. After incubation, the Adhesive Foil was taken off, the contents were 
aspirated, then 300μL of washing solution was added to each well and 
aspirated. The wash step was repeated for total of five times with 
approximately 300μL/well of washing solution each time and finally invert the 
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plate and tap it firmly on a lint free paper towel to ensure blotting free of most 
residual washing solution. 
5. One hundred microliter of SA-HRP Solution into each well was pipetted. 
6. The plate with Adhesive Foil was covered and incubated at room 
temperature for 1 hour (still or shaking). 
7. The Adhesive Foil was taken off, the wells were aspirated and washed five 
times as procedure 4. 
8. One hundred microliter of TMB Substrate was added into each well; the 
plate was covered with Adhesive Foil and kept for 30minutes (still or shaking) 
at room temperature under a light proof condition. 
9. One hundred microliter of reaction Stopping Solution was added into each 
well to stop coloring reaction. 
10. The optical absorbance of the wells was read at 450nm. 
11. Mean optical density values of wells containing standard solutions or their 
bound percentage (B/Bo%) to Bo wells (0 ng/mL standard as Bo) was 
calculated and a standard curve on a semi-logarithmic graph paper (abscissa: 
concentrations of standard; ordinate: optical density or B/Bo%) was plotted. 
The average optical density or B/Bo% of each sample was used to determine 






Assay range > 
0.412 – 100ng/mL 
 
3.7.2 Determination of glycohemoglobin (HbA1c) in whole 
blood 
HbA1c was determined by the colorimetric determination of glycohemoglobin 
in whole blood using Stanbio Kit, Texas-USA. 
 
Principle 
A preparation of hemolyzed whole blood is mixed with a weakly binding cation 
exchange resin. The non-glycosylated hemoglobin HbA0 binds to the resin, 
leaving HbA1 free to be removed by means of a resin separator in the 
supernate. The percent of HbA1 is determined by measuring the absorbance 
values at 415 nm of the HbA1 fraction and of the total Hemoglobin fraction, 
calculating the ratio of absorbances (R), and comparing this ratio to that of a 
glycohemoglobin standard carried through the same procedure. 
Results are express as HbA, but can be converted or derived as HbA1c by 




Glycohemoglobin lon Exchange Resin. Each tube contains 3.0 mL 
cation exchange resin 8 mg/dL. pH 6.9 
Glycohemoglobin Lysing Reagent 
contains potassium cyanide 10 mmol/L and surfactants. 
Glycohemoglobin Standard (Lyophilized) (1 vial) 




1. Five hundred microliter lysing reagent was pipetted into tubes labeled 
Standard (S), Unknown (U) and Control (C). 





3. Tubes was allowed to stand for 5 minutes at room temperature (15-30°C) to 
complete hemolysis. 
 
Glycohemoglobin separation and assay 
1. Resin tubes was labeled Standard (S), Unknown (U) and Control (C). 
2. One hundred microliter was pipetted of the prepared hemolysate into 
appropriately labeled resin tube. 
3. A resin separator was positioned in the tube so rubber sleeve is 
approximately 1-2 cm above liquid level. 
4. Tubes were mixed on a hematology rocker for 5 minutes. Alternatively 
tubes may be mixed by hand if held above the resin. 
5. At the end of the 5 minute mixing, resin separator was pushed into tube 
until resin is firmly packed in bottom of the 13mm tube. 
6. Each supernate was poured directly into separate cuvettes for absorbance 
measurements. 
7. Absorbance was read (Agly) of Standard, Unknown and Control vs. water 
at 415 nm within 60 minutes. 
 
Total hemoglobin assay 
1. Five milliliter deionized water was pipetted into tubes labeled Standard (S), 
Unknown (U) and Control (C). 
2. Twenty microliter of hemolysate was pipetted into appropriately labeled 
tube and mixed well and transferred to cuvette for absorbance reading. 
3. Absorbance (Atot) of Standard was read, Unknown and Control vs. water at 
415 nm within 60 minutes. 
 
Calculation 
For each Standard and Unknown calculate the ratio (R) of the 
glycohemoglobin absorbance to the hemoglobin absorbance as follows: 
                                            (R) = Agly / Atot 
 
Hemoglobin (%) = (R) Unknown x Hemoglobin Standard (%) 
                                             (R) Standard 
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Results may also be reported as HbA1c when compared to the reference A1c 
method, the Stanbio method showed a 98% correlation with an equation of: 
                   Y (A1c value) = 0.838 x (Stanbio value) - 0.732 
 
The value obtained by the Stanbio method may be converted to Calculated 
A1c value by use of this formula. For a direct calculated A1c value, the value 
of the standard may be changed to 7.6% in lieu of the 10.0% and the results 
will be A1c values. 
 
3.7.3 Determination of serum glucose 
 
Principle 
Determination of glucose after enzymatic oxidation by glucose oxidase. The 
colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action 
of peroxidase. 
 













≥ 15 ku/l 
≥ 1 ku/l 
Phosphate buffer (pH 7.5) 
Phenol   
4-Aminoantipyrine 
Glucose oxidase (GOD) 
Peroxidase (POD)   









Wavelength:   500 nm 
Optical path:  1 cm 
Temperature: 37 ºC 
Measurement: Against reagent blank. 
 10 µl of standard (sample or control) was added to 1ml of the reagent 
and mixed well. 
 The mixture was incubated for 10 min at 37 ºC.  
 The absorbance was measured within 60 min.  
 
Calculation 






Reference value (fasting glucose) 
(Palestinian clinical laboratory tests guide, PCLTG, 2005) 
60 – 100 mg/dl Child 
70 – 110 mg/dl Adult 
 
 
3.7.4 Determination of serum cholesterol 
Enzymatic colorimetric method for the quantitative determination of total 
cholesterol in serum or plasma, using Diasys Diagnostic Systems, Germany. 
 
Principle 
Determination of cholesterol after enzymatic hydrolysis and oxidation. The 
colorimetric indicator is quinoneimine which is generated from 4-











Cholesterol + O2→   cholesterol-3-one + H2O2 
 
 










≥ 200 u/l 
≥ 100 u/l 
≥ 3 ku/l 
Good’s buffer (pH 6.7)   
Phenol 
4- Aminoantipyrine 
Cholesterol esterase (CHE) 
Cholesterol oxidase (CHO) 
Peroxidase (POD) 




Wavelength: 500 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against reagent blank. 
 Ten µl of standard (sample or control) was added to 1ml of working 
reagent and mixed well. 
 The mixture was incubated for 5 min at 37 ºC.  















Child (desirable)      < 170 mg/dl 




3.7.5 Determination of serum triglycerides 
 
Enzymatic colorimetric method for the quantitative determination of total 




Determination of triglycerides after enzymatic splitting with lipoprotein lipase. 
Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4-
chlorophenol by hydrogen peroxide under the catalytic action of peroxidase.  
 
Triglycerides →Glycerol + fatty acid 
 
Glycerol + ATP→  Glycerol-3-phosphate + ADP 
 
Glycerol-3-phosphate    + O2 →Dihydroxyaceton  phosphate + H2 O2 
 




Concentrations are those in the final test mixture. 
Reagent Concentration 




50  mmol/l 
4   mmol/l 








Glycerokinase   (GK)   
Peroxidase    (POD) 
Lipoprotein lipase   (LPL) 
4-Aminoantipyrine 
Glycerol-3-phosphate-oxidase (GPO) 
≥ 0.4 KU/I 
≥  2  KU/I 
≥  2  KU/I 
0.5 mmol/l 
≥ 0.5 KU/I 
Standard 200 mg/dl 
 
Assay Procedure  
Wavelength:   500 nm 
Optical path:  1 cm 
Temperature: 37 ºC 
Measurement: Against reagent blank. 
 Ten µl of standard (sample or control) was added to 1ml of working 
reagent and mixed well. 
 The mixture was incubated for 5 min at 37 ºC.  






Triglycerides [mg / dl] =  
 
 
Reference value  
30 - 150 mg/dl Child (desirable) 
40 - 160 mg/dl 
35  - 135 mg/dl 
Adult (desirable)    M 
                               F 
 
 
3.7.6 Determination of serum high density lipoprotein 
cholesterol (HDL-C) 
Liquid HDL-C precipitant for the determination of HDL-C Cholesterol using 
Diasys Diagnostic Systems, Germany. 
 
 





Chylomicrons, VLDL-C and LDL-Cwere precipitated by adding 
phosphotungstic acid and magnesium ions to the sample. Centrifugation 
leaves only the HDL-C in the supernatant, their cholesterol content is 





8.6 mmol/l    
Monoreagent contain: Magnesium chloride 
                                    Phosphotungstic acid 
200 mg/dl Choesterol standard 
 
Assay procedure  
 
1- Precipitation  
 Two hundred µl of standard (sample or control) were added to 500 µl of 
the precipitation reagent and mixed well. 
 The mixture was allowed to stand for 15 min at room temperature, and 
then centrifuged for 20 min at 4000 rpm.  
 
2- Cholesterol determination 
Wavelength: 500 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against reagent blank. 
 One hundred µl of the supernatant of standard (sample or control) was 
added to 1ml of the cholesterol reagent and mixed well. 
 The mixture was incubated for 5min at 37 ºC.  















3.7.7 Determination of serum low density lipoproteins 
cholesterol (LDL-C) 




The ultracentrifugal measurement of LDL-C is time consuming and expensive 
and requires special equipment. For this reason, LDL-C is most commonly 
estimated from quantitative measurements of total and HDL-C and plasma 
triglycerides (TG) using the empirical relationship of Friedewald. 
 
The Equation 
LDL-C = Total Cholesterol - HDL-C - TG/5 
 
 
3.7.8 Determination of serum urea  
 
Serum Urea was determined by urease - glutamate dehydrogenase 
(GDH)/UV method using BioSystems kit, Spain. 
 
Principle 
Urea in the sample is consumed, by means of the coupled reactions 
described below. The decrease of NADH can be measured photometrically at 
340 nm. 
Urea + 2H2O→2NH4 + 2HCO 
37 – 75 mg/dl Child 
35 – 65 mg/dl 
35 – 80 mg/dl 
Adult: M 













≥ 0.6 ku/l 






0.25 mmol/l R2: NADH 





The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 340 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against distilled water. 
 10 µl of standard (sample or control) was added to 1ml of working 
reagent and mixed well. 
 The mixture was incubated for 30 sec then absorbance (A1) was 
recorded. 




∆A = (A1 –A2) sample or standard 
 
Urea (mg/dl) =  
 
GLDH 





Reference value  
(PCLTG, 2005) 
Child 5 - 30 mg/dl 
Adult 13 - 43 mg/dl 
 
 
3.7.9 Determination of serum creatinine  
Serum Creatinine was determined by Alkaline Picrate method using 




Creatinine forms a colored orange-red complex in an alkaline picrate solution. 
The difference in absorbance at fixed times during conversion is proportional 
to the concentration of creatinine in the sample. 
Creatinine + Picric acid → creatinine picrate complex 
 
Reagents 
Concentrations are those in the final test mixture. 
Concentration Reagent 
0.16 mol/l R1: Sodume hydroxide (pH approx. 13) 
4.0 mmol/l R2: Picric acid (pH approx. 1.2) 




The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 490 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement:  against distilled water. 
 50 µl of standard (sample or control) was added to 1ml of working 
reagent add and mixed well. 
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 The Mixture was incubated for 60 sec then absorbance(A1) was 
recorded. 
 After exactly further 120 sec the absorbance (A2) was measured. 
 
Calculation 
∆A = (A1 –A2) sample or standard 
 




Reference value (PCLTG, 2005) 
Infant 0.2 – 0.4 mg/dl 
Child 0.3 - 0.7 mg/dl 
Adolescent 0.5 - 1.0 mg/dl 
Adult:  M 
            F 
0.6 - 1.2 mg/dl 



















3.8 Statistical analysis 
 
Data were computer analyzed using SPSS/ PC (Statistical Package for the 
Social Science Inc. Chicago, Illinois USA, version 18.0) statistical package. 
 Simple distribution of the study variables and the cross 
tabulation were applied.  
 Chi-square (2) was used to identify the significance of the 
relations, associations, and interactions among various 
variables. Yates’s continuity correction test, 2(corrected), was used 
when not more than 20% of the cells had an expected frequency 
of less than five and when the expected numbers were small.  
 The independent sample t-test procedure was used to compare 
means of quantitative variables by the separated cases into two 
qualitative groups such as the relationship between cases and 
controls obestatin hormone. 
 Pearson's correlation test was applied.  
 The results in all the above mentioned procedures were 
accepted as statistical significant when the p-value was less 
than 5% (p<0.05). 
 Range as minimum and maximum values was used.  
 The percentage difference was calculated according to the 
formula: Percentage difference equals the absolute value of the 
change in value, divided by the average of the 2 numbers, all 
multiplied by 100. 
          Percent difference = (| (V1 - V2) | / ((V1 + V2)/2)) * 100. 
 Microsoft Excel program version 11.0 was used for correlation 











4.1 Sociodemographic data of the study population 
The present study is a case control design. The study population comprised 
64 diabetic women (case group) and 64 healthy control women. Table 4.1 
summarizes the sociodemographic data of the study population. Age 
classification showed that 28 (43.7%) controls and 27 (42.2%) cases were 40-
50 years old. Age group 51-60 years comprised 24 (37.5%) controls and 26 
(40.6%) cases. Controls and cases aged >60 years old were 12 (18.8%) and 
11 (17.1%), respectively. The difference between controls and cases in term 
of age distribution was not significant (2=0.142, P=0.931). The mean ages of 
controls and cases were 52.7±8.9 and 52.9±8.3 years old with ranges of 40-
65 and 40-64 years, respectively. The independent sample t-test also showed 
no significant difference between mean ages of controls and cases (t=0.113, 
P=0.911). Analysis of the educational status of the study population showed 
that 13 (20.3%) controls and 20 (31.3%) cases had diploma or university 
degree, 14 (21.9%) and 14 (21.9%) had finished secondary school, 25 
(39.1%) and 16 (25.0%) had finished preparatory school, 3 (4.7%) and 8 
(12.5%) had passed primary school, and 9 (14.1%) and 6 (9.4%) were 
illiterate, respectively.  The difference between various educational levels of 
controls and cases was not significance (2(corrected)=4.409, 
P=0.353).Regarding family history, 41 (64.1%) controls and 52 (81.2%) cases 
had family history of diabetes whereas 23 (35.9%) and 12 (18.8%) had not. 
The difference between the two groups was significance (2=4.758, P=0.029), 













































Mean±SD 52.7±8.9 52.9±8.3 t 0.113 0.911 
Range (min-max) 40-65 40-64  
Education 

































































4.2 Diet and drug therapy among the study population 
Table 4.2 illustrates diet and drug therapy among the study population. The 
number of controls and cases on diet were 16 (25.0%) and 30 (46.9%), 
respectively whereas those who were not were 48 (75.0%) and 34 (53.1). The 
difference between the two groups was significant (2=6.651, P=0.010). 














Table 4.2.Diet and drug therapy among the study population  
Character Controls 
(n=64) 



























































4.3 Distribution of diabetic patients by the duration of 
the disease 
Table 4.3 demonstrates the distribution of diabetic patients by the duration 
of the disease. Patients with diabetes since less than 5 years were 38 
(59.4%), whereas those with diabetic duration of 5-10 years were 14 




Table 4.3. Distribution of diabetic patients (n=64) by the duration of the disease 
Duration of diabetes (Year) No. % 
< 5 38 59.4 
5-10 14 21.9 







4.4 Self-reported complications of the study 
population 
The main self-reported complications among diabetic patients and controls 
are summarized in Table 4.4. The percentages of retinopathy and 
neuropathy were higher in cases compared to controls (37.5 and 43.8% vs 
12.5 and 14.1%, respectively) with statically significant differences 
(2(corrected)=10.667, P=0.001 and 2(corrected)=13.724, 
P=0.000,respectively). However, no significant difference was found 

























  Yes 











  Yes 








*P-value of 2(corrected) test. **CVD: Cardiovascular diseases. P>0.05: not 




4.5 Self-reported complications among patients in 
relation to the duration of diabetes  
Self-reported complications among patients in relation to the duration of 
diabetes is provided in Table 4.5. In general, the longer the duration of 
diabetes mellitus, the higher the percentage of self-reported complications 
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among patients. This positive relationship was statically significant for 
retinopathy (2=6.210, P=0.045) and neuropathy (2=6.934, P=0.031). On 




Table 4.5. Self-reported complications among patients in relation to the duration of 
diabetes 







> 10 (n=12) 
n (%) 
Retinopathy(n=24) 9 (23.7) 7 (50.0) 8(66.7) 6.210 0.045 
CVD**(n=4) 2 (5.3) 1 (7.1) 1 (8.3) 0.267 0.875* 
Neuropathy(n=28) 11(28.9) 8(57.1) 9(75.0) 6.934 0.031 
*P-value of 
2





4.6 Anthropometric measurements of the study 
population 
Table 4.6 shows the anthropometric measurements of the study population. 
The mean weight of controls was 88.3±21.6 kg compared to 88.5±17.4 kg of 
cases. The weight difference was not significant (t=0.173 and P=0.864) with 
% difference=0.2. There was also a none significant difference in the mean 
height of cases compared to controls (1.58±0.06 vs.1.59±0.06 m, % 
difference=0.6, t=0.894 and P=0.375). Therefore, no significant difference was 
found in BMI of cases versus controls (35.2±6.5 vs. 34.4±7.7, % 







































2.3% 0.281 0.780 
*Kg: kilogram,** m: meter. ***BMI: Body mass index: Normal=18.5-24.9, Obese≥30 (WHO, 
2000).All values are expressed as mean ±SD. P>0.05: not significant. 
 
4.7 Serum obestatin levels of the study population 
The average serum obestatin levels in controls and cases is presented in 
Table 4.7. There was a significant decrease in the mean level of obestatin in 
cases compared to controls (3.4±0.8 vs. 4.1±1.5 ng/ml, % difference=18.6, 
t=2.328 and P=0.023). 
 
 

















18.6 2.328 0.023 





4.8 HbA1c and glucose of the study population 
As indicated in Table 4.8, the mean HbA1c and glucose levels in cases 
were significantly higher than that in controls (6.4±0.9% and 190.7±86.7 
mg/dl vs. 4.7±0.6% and 101.6±21.0 mg/dl, % difference= 30.6 and 60.9, 





















30.6 9.136 0.000 






60.9 5.726 0.000 




4.9 Serum lipid profile of the study population 
Table 4.9 illustrates serum lipid profile of the study population including 
cholesterol, triglycerides, HDL-C and LDL-C of cases and controls. The 
average levels of cholesterol and triglycerides were found to be higher in 
cases (194.8±44.7 and 183.3±80.0 mg/dl, respectively) compared to controls 
(188.1±38.3 and 122.4±42.9 mg/dl, respectively) with % differences of 3.5 and 
39.8%, respectively). However, this increase was statistically significant for 
triglycerides (t=3.841, P=0.000). No statistically significant change was found 
for LDL-C between cases and controls. On the other hand, HDL-C was 
significantly lower in cases compared to controls (40.7±11.2 vs. 47.2±12.0  







































  (67-265) 
183.3±80.0 
  (75-391) 
39.8 3.841 0.000 






1.0 0.101 0.920 






14.8 2.228 0.030 
*LDL-C: Low density lipoprotein cholesterol, **HDL-C: High density lipoprotein cholesterol. All 
values are expressed as mean ±SD. P>0.05: not significant, P<0.05: significant. 
 
 
4.10 Serum urea and creatinine of the study 
population 
Serum urea and creatinine concentrations of the study population are 
clarified in Table 4.10. There was a border line significant increase in urea 
concentration in cases compared to controls (26.0±8.1 vs 23.1±3.7mg/dl, 
% difference=11.8, t=1.871, P=0.066). However, such increase was not 
statistically significant for creatinine (0.74±0.2 vs 0.73±0.1 mg/dl, % 
































11.8 1.871 0.066 
Creatinine 





1.4 0.108 0.914 
Reference range: urea=15-43 mg/dl (Thomus, 1998) and creatinine=0.6-1.1 mg/dl(Newman 




4.11 Obestatin levels in relation to BMI of the study 
population 
Obestatin level in relation to BMI of the study population is presented in Table 
4.11. The Pearson correlation test showed that the higher the BMI, the lower 
the level of obestatin. However, this negative correlation was not statistically 
significant (r=-0.068, P= 0.590). 
 
 







BMI* -0.068 0.590 
* Women with BMI=18.5–24.9 were considered to have normal weight, Women with 




4.12 Obestatin levels in relation to HbA1c and glucose 
of the study population 
Table 4.12 and Figures 4.1 and 4.2 present the relationship between 
obestatin level with HbA1c and glucose of the study population. Obestatin 
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showed significant negative correlation with HbA1c and glucose (r=-0.320, P= 
0.009 and r=-0.469, P= 0.000, respectively). 
 
 







HbA1c -0.320 0.009 





Figure 4.1. Correlation between obestatin hormone level with HbA1c of the study 
population. 
 
Figure 4.2. Correlation between obestatin hormone level with fasting blood glucose level of 
the study population. 
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4.13 Obestatin levels in relation to lipid profile of the 
study population 
The relationship between obestatin and lipid profile of the study population is 
demonstrated in Table 4.13. The Pearson correlation test showed that with 
decreasing obestatin levels there are increases in cholesterol, triglycerides 
and LDL-C levels. Such negative correlation was significant only for 
triglycerides (Figure 4.3, r=-0.275, P=0.026). On the other hand, there is a 
positive correlation between obestatin level and HDL-C and this correlation 
was also not significant (r=0.024, P=0.848). 
 
 








Cholesterol -0.175 0.164 
Triglycerides -0.275 0.026 
*LDL-C -0.090 0.474 
**HDL-C 0.024 0.848 
P>0.05: not significant. *LDL-C: Low density lipoprotein cholesterol, **HDL-C: High density 








4.14 Obestatin levels in relation to urea and creatinine 
of the study population 
As illustrated in Table 4.14, there were no significant positive correlations 
between obestatin levels and urea and creatinine concentrations (r=0.000, P= 
0.997 and r=0.209, P= 0.096,respectively). 
 
 







Urea 0.000 0.997 





















Diabetes mellitus has in the last decade become a global problem. The total 
number of people with diabetes is projected to rise from 171 million in 2000 to 
366 million in 2030. There are more women with diabetes than men (Wild et 
al., 2004). Despite its high prevalence and the subsequent health problems, 
there are under-diagnosis and under-reporting of diabetes mellitus in the 
Gaza Strip. Biochemical tests of the disease were restricted to monitoring 
blood glucose level when the patient visits the clinic. Recently, few studies 
have been focused on the determination of leptin, insulin and ghrelin in type 2 
diabetic patients in Gaza Strip (Altawil, 2009 and Abu Snayma, 2012). 
However, no previous study investigated the role of the novel hormone 
obestatin in diabetes mellitus. Therefore, the present work is the first to 
assess obestatin status in type 2 diabetic women from Gaza. 
 
 
5.1 Family history and diet among the study 
population 
The Chi square test showed that the number of cases who had family history 
of diabetes was significantly higher than that of controls. This indicates that 
family history is associated with type 2 diabetes. Such finding is in agreement 
with that obtained by Annis et al., (2005); Pijl et al., (2009) and Abu Mustafa, 
(2011) who reported that family history is a risk factor for type 2 diabetes. 
Although there was a significant association between diabetes and diet, about 
half of the patients were not on diet. Previous work carried out in Gaza Strip 
showed such significant association(Altawil, 2009 and Abu Mustfa). This 
necessitates launching of educational programs to show the importance of 
diet in controlling the disease. Watkins (2003) reported that healthy eating is 
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the cornerstone of diabetic treatment, and control of the diet should always be 
the first treatment offered to Type 2 diabetic patients before drugs are 
considered. In this context, the most common used antidiabetic drug among 
type 2 diabetic patients in Gaza is glucophage.  
 
5.2 Diabetes duration and Self-reported 
complications 
The finding that more than half of patients had diabetes since less than 5 
years do confirm the idea that type 2 diabetes has long asymptomatic pre-
clinical phase which frequently goes undetected. At the time of diagnosis, the 
patient could have one or more diabetes complications i.e. there is a latent 
phase before diagnosis of Type 2 diabetes. During this period of undiagnosed 
disease, risk factors for diabetic micro- and macrovascular complications are 
markedly elevated and diabetic complications are developing (Canadian 
Diabetes Association Clinical Practice Guidelines Expert Committee, 2003 
and Watkins, 2003). The relation between diabetes duration and self-reported 
complications confirmed this view. However, this point still needs further 
investigation. The most self-reported symptoms among diabetic patients were    
neuropathy and retinopathy. The prevalence of such symptoms was positively 
associated with the progress of the disease i.e. the longer the duration of 
diabetes mellitus, the higher the percentage of self-reported complications 
among patients. Several studies reported similar diabetic complications with 
increasing rates upon disease progress (Savage, 1996, Dyck et al., 2002, 
Marshall, 2006 and The National Eye Institute, 2006, Altawil, 2009 and Abu 
Sunayma, 2012). 
 
5.3 Diabetes and body mass index 
Body mass index provides a reliable indicator of body fatness for most 
people and it is used to screen for weight categories that may lead to health 
problems (CDC, 2007). Therefore, obesity is commonly defined as a BMI of 
30 kg/m2 or higher. This definition distinguishes obesity from being pre-
obese or  overweight, which is classified as a BMI of 25 kg/m2 but less than 
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30 kg/m2 (WHO, 2000). In the present study, both controls and cases were 
obese. This masked the prospective significant association between BMI 
and diabetes which was mentioned by Marshall (2006) and Yassin et al. 
(2011).  Nevertheless, matching this confounder factor may reveal the real 
status of obestatin in diabetic patients regardless of their body mass index. 
 
 
5.4 Serum obestatin of the study population 
Result presented in this study revealed that the mean level of obestatin was 
significantly decreased in type 2 diabetic women compared to healthy non 
diabetic controls. This finding is in agreement with that observed by Catalán et 
al. (2007); Qi et al. (2007); St-Pierre et al. (2010) and Jack, (2012). On the 
other hand, Lippl et al. (2008) reported that basal obestatin levels in patients 
with type 2 diabetes were not different compared to nondiabetic subjects. This 
contradiction may be explained on basis of different sample size, gender, age, 
BMI and pre- or postprandial periods. Therefore, well-controlled human 
studies collecting multiple measures of obestatin before and after a meal are 
needed. In addition, a better understanding of the biological mechanism of 
action of obestatin, i.e., through identification of its receptor, could help to 
explain these findings. 
 
 
5.5 HbA1c and glucose of the study population 
As indicated in the present results, the mean HbA1c and glucose levels in 
cases were significantly higher than that in controls. Similar results were 
obtained by Qi et al. (2007) and Yassin et al. (2011) who found that type 2 
diabetic patients had higher fasting glucose and HbA1C levels than non-
diabetics. In diabetes, prolonged hyperglycemia superdrives nonenzymatic 
protein glycation, which forms reversible Schiff bases and Amadori 
compounds. A series of further complex molecular rearrangements then yield 
irreversible advanced glycosylated end-products (AGEs). AGEs accumulate in 
the circulating blood and in various tissues (Furth, 1997). It is reported that the 
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levels of HbA1c in the blood reflect the glucose levels to which the erythrocyte 
has been exposed during its lifespan (Goldstein, 2004). Therefore, the HbA1c 
test is attractive as it measures chronic glycaemia, rather than instantaneous 
blood glucose levels. HbA1c has been used as an objective marker of 
average glycaemic control for many years, has an accepted place in the 
monitoring of patients with diabetes, and is relied on for significant 
management decisions, such as initiation of insulin therapy (d´Emden et al., 
2012). In the present study, the Pearson correlation test showed negative 
significant correlations between obestatin levels and HbA1c and glucose. 
Similar result was documented by Qi et al. (2007) and Lippl et al.(2008). This 
negative relationship reflects the change of the glycemic parameter with 
obestatin and suggests an involvement of obestatin signalling in glucose 




5.6 lipid profile of the study population 
The present results demonstrate significant increase in triglyceride levels of 
cases compared to controls. On the other hand, HDL-C level was significantly 
decreased in cases. Elevation of triglycerides in diabetic patients was 
documented by several authors (Chen et al., 2009; Katsiki et al., 2011 and Al-
Hakeim and Ali 2012). The general increase levels of  serum  lipids  in  
diabetic patients  may be mainly attributed to increase  in  the mobilization of  
free  fatty acids  from  fat depots, since elevation of insulin inhibits the 
hormone sensitive lipase. Then, excess fatty acids in serum are converted 
into triglycerides, phospholipids and cholesterol in liver (Scheen, 2003). The 
Pearson correlation test showed negative significant correlation between 
obestatin and triglycerides level. Similar finding was observed by Nagaraj et 
al. (2008 and 2009) and Agnew et al. (2011). It was reported that obestatin is 
a metabolic hormone capable of binding to GPR39 receptor to regulate the 
functions of adipose tissues (Zahng, 2008). In this context, Miegueu et al. 
(2011) showed that fatty acid uptake was increased three- to fourfold in a 
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concentration-dependent manner with obestatin. Therefore, the decreased 
level of obestatin observed in the present study is expected to increase serum 
triglycerides in diabetic patients. 
 
5.7 Urea and creatinine concentrations of the study 
population 
Data provided in the present study showed no significant increase in urea and 
creatinine concentrations in diabetic patients compared to controls. Similar 
results were documented by Altawil (2009) and Abu Snayma. Urea is formed 
by the liver as an end product of protein breakdown and creatinine is a waste 
product that is normally filtered from the blood and excreted with the urine.  
Creatinine  and  urea  are  markers  of  the  kidney function  and  changes  in  
their  levels  are  indicating  renal  diseases  (Debra Manzella,  2008).  
Therefore,  the  results  indicated  that many  of  the  studied diabetic patients 
are  still  in  the early stages of  the disease. This was obvious in the finding 
that more than half of the patients had diabetes since less than 5 years. 
However, it was difficult to determine the onset of such changes in urea and  
creatinine  concentrations  and  this  may  lead  to  controversial  results 
(Varghese  et  al.,  2001  and El Meligi  et al., 2003). Therefore, the creatinine 
levels must be watched carefully to determine how much function the kidneys 



















 The mean ages of controls and cases were 52.7±8.9 and 52.9±8.3 
years. 
 Type 2 diabetes was found to be associated with family history and 
diet. 
 More than half of patients had diabetes since less than 5 years. 
 The main self-reported complications among patients were neuropathy, 
retinopathy and cardiovascular disease. The longer the duration of 
diabetes, the higher the prevalence of self-reported complications. 
 The mean level of serum obestatin was significantly lower in diabetic 
women compared to healthy non diabetic controls (3.4±0.8 ng/ml vs. 
4.1±1.5 ng/ml, P=0.023). 
 The mean HbA1c and glucose levels in cases were significantly higher 
than that in controls (6.4±0.9 and 190.7±86.7 vs 4.7±0.6 and 
101.6±21.0) with P=0.000. The Pearson correlation test showed negative 
significant correlations between obestatin levels and HbA1c and 
glucose (r=-0.320, P=0.009 and r=-0.469, P=0.000, respectively).  
 The average level of triglycerides was significantly increased in diabetic 
women (183.3±80.0mg/dl) compared to controls (122.4±42.9 mg/dl) 
with P=0.000. On the other hand, HDL-C was significantly lower in 
cases (40.7±11.2 vs. 47.2±12.0 mg/dl, % difference=14.8 and t=2.228, 
P=0.030). The Pearson correlation test showed negative significant 








 Assessment the status of obestatin hormone in diabetes could 
constitute a promising therapy of the disease. In this context, multiple 
measures of obestatin in pre- and post-prandial periods are needed. 
 
 Launching of health education programs on diabetes particularly 
among women with family history of diabetes and those who are not on 
diet are highly recommended. 
  Regular visits to neurological and optical clinics to take early steps to 
avoid and manage diabetic complications concerning diabetic 
neuropathy and retinopathy. 
 
  Further research is highly recommended on obestatin and the 






















I am a researcher / Mona M. Hamam (Master student/ The Islamic University 
of Gaza) will be very grateful if you help me in completing this study which 
focuses on the role of a novel hormone obestatin in type 2 diabetes in women 
from Gaza Governorate, Gaza strip. 
 
Personal data 
 Tel. No. 
 Name(Optional) 
 Age 
□University or diploma □Secondary school 
□Preparatory school □Primary school 
□illiterate 
Education 
□ Yes□No Family history of diabetes 
Height:          cm Weight:            Kg BMI 
□ Yes□No Diet 
Clinical data(Only for diabetic patients) 
 Age at diagnosis 
 Duration of diabetes 
 Type of drug used 
Complications 
□ Yes□No Retinopathy 
□ Yes□No Cardiovascular diseases 
□ Yes□No Neuropathy 
□ Yes□No Recurrent infections 
□ Yes□No Skin lesions 
□ Yes□No Oral cavity lesions 
 
 






 أجل من االستبٌان هذا تعبئة فً المساعدة أرجو).  اإلسالمٌة بالجامعة ماجستٌر طالبةمنى حمام ) /الباحثة أنا








ثانوٌة عامة  جامعة او دبلوم   □ □ 
□المرحلة االبتدائٌة   □أمً المرحلة االعدادٌة  □ 
 من السكري مرض من عائلتك أفراد أحد ٌعانً هل
 ال □نعم                   □ الثانً؟ النوع
BMI :الوزن:                  الطول 
 هل تتبع حمٌة غذائٌة ؟
 ال □نعم                   □
 بيانات طبية )خاص بمرضى السكري(
  المرض؟ تشخٌص وقت عمرك انك مك
  لدٌك؟ مرة ألول السكري تشخٌص تم عام أي فً
  ما هو نوع العالج  الذي تتناوله؟
 مضاعفات مرض السكري
 يهالع في لكمشا
 ال □وعم                   □
 القلة أمراض
 ال □وعم                   □
 ال □وعم                   □ األعصاب في لكمشا
 عدوى متكررة 
 ال □وعم                   □
 مشاكل في الجلد
 ال□وعم                   □
 تقرحات في الفم
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